3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Breast Neoplasms
10
Pain, Postoperative
7
Lung Neoplasms
4
Depression
4
Brain Neoplasms
4
Anxiety Disorders
4
Prostatic Neoplasms
3
Pain
3
Ovarian Neoplasms
3
Neoplasms
3
Colonic Neoplasms
3
Agnosia
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Fallopian Tube Neoplasms
2
Delirium
2
Colorectal Neoplasms
2
Warts
1
Uterine Cervical Neoplasms
1
Trauma, Nervous System
1
Thrombosis
1
Synovial Cyst
1
Stroke
1
Spondylosis
1
Spondylolisthesis
1
Spinal Stenosis
1
Sleep Initiation and Maintenance Disorders
1
Sigmoid Neoplasms
1
Sepsis
1
Interventions
Fluorouracil
16
Oxaliplatin
14
Nivolumab
14
Leucovorin
13
pembrolizumab
9
Paclitaxel
9
Capecitabine
9
Radiotherapy
6
Radiation
6
durvalumab
5
Taxes
5
Irinotecan
5
Cisplatin
5
Trastuzumab
4
Specimen Handling
4
Drug Therapy
4
Carboplatin
4
tremelimumab
3
dehydroftorafur
3
Ramucirumab
3
Magnetic Resonance Spectroscopy
3
Folfox protocol
3
Endoscopy
3
Docetaxel
3
Biopsy
3
zimberelimab
2
zanidatamab
2
trastuzumab deruxtecan
2
tislelizumab
2
futibatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma Of Esophagus
×
Saline Solution
×
1 year
×
Clear all
NCT04210115
2026-05-13
KEYNOTE 975
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
703 enrolled